Stargardt Disease Stgd Pipeline Insight

DelveInsight’s, “Stargardt Disease (STGD) - Pipeline Insight, 2022,” report provides comprehensive insights about 18+ companies and 18+ pipeline drugs in Stargardt Disease (STGD) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. 

Geography Covered

  • Global coverage

Stargardt Disease (STGD) Understanding

Stargardt Disease (STGD): Overview

Stargardt Disease (STGD) is an inherited disorder of the retina — the tissue at the back of the eye that senses light. The disease typically causes vision loss during childhood or adolescence, although in some forms, vision loss may not be noticed until later in adulthood. It is rare for people with the disease to become completely blind. For most people, vision loss progresses slowly over time to 20/200 or worse. (Normal vision is 20/20). The most common symptom of Stargardt Disease (STGD) is variable, often slow loss of central vision in both eyes. People with the disease might notice gray, black, or hazy spots in the center of their vision, or that it takes longer than usual for their eyes to adjust when moving from light to dark environments. Their eyes may be more sensitive to bright light. Some people also develop color blindness later in the disease.


"Stargardt Disease (STGD) - Pipeline Insight, 2022" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Stargardt Disease (STGD) pipeline landscape is provided which includes the disease overview and Stargardt Disease (STGD) treatment guidelines. The assessment part of the report embraces, in depth Stargardt Disease (STGD) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Stargardt Disease (STGD) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Stargardt Disease (STGD) R&D. The therapies under development are focused on novel approaches to treat/improve Stargardt Disease (STGD).

Stargardt Disease (STGD) Emerging Drugs Chapters

This segment of the Stargardt Disease (STGD) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.


Stargardt Disease (STGD) Emerging Drugs


Emixustat hydrochloride: Kubota Vision

Emixustat modulates the visual cycle by inhibiting a critical enzyme of this pathway, retinal pigment epithelium protein 65 (RPE65). The visual cycle is the process by which vitamin A is recycled in the eye; vitamin A is crucial to the visual process. Slowing the visual cycle reduces the availability of vitamin A derivatives (11-cis- and all-trans-retinal) to form precursors of toxic A2E and related compounds. In addition, reducing the availability of 11-cis-retinal decreases retinal metabolic demands under dark conditions. Currently, it is in Phase III stage of clinical trial evaluation to treat Stargardt Disease (STGD).


ALK-001: Alkeus Pharmaceuticals

ALK-001 is a chemically-modified vitamin A being investigated for the prevention and treatment of Stargardt Disease (STGD) and age-related macular degeneration (AMD). ALK-001 is taken once a day by mouth. Toxic vitamin A aggregates (“dimers”) have been implicated in the pathophysiology of Stargardt and dry-AMD. Vitamin A dimers form when two molecules of vitamin A are combined. ALK-001 is a form of vitamin A that has been chemically-modified to slow the formation of toxic vitamin A dimers in the eye.

Further product details are provided in the report……..

Stargardt Disease (STGD): Therapeutic Assessment

This segment of the report provides insights about the different Stargardt Disease (STGD) drugs segregated based on following parameters that define the scope of the report, such as:

  • Major Players in Stargardt Disease (STGD)

There are approx. 18+ key companies which are developing the therapies for Stargardt Disease (STGD). The companies which have their Stargardt Disease (STGD) drug candidates in the most advanced stage, i.e. phase III include, Kubota Vision.

Phases

DelveInsight’s report covers around 18+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration


Stargardt Disease (STGD) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • Intravitreal
  • Subretinal
  • Topical.
  • Molecule Type


Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Stargardt Disease (STGD): Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Stargardt Disease (STGD) therapeutic drugs key players involved in developing key drugs.


Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Stargardt Disease (STGD) drugs.

Stargardt Disease (STGD) Report Insights

  • Stargardt Disease (STGD) Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Stargardt Disease (STGD) Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Stargardt Disease (STGD) drugs?
  • How many Stargardt Disease (STGD) drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Stargardt Disease (STGD)?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Stargardt Disease (STGD) therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Stargardt Disease (STGD) and their status?
  • What are the key designations that have been granted to the emerging drugs?

Introduction

Executive Summary

Stargardt Disease (STGD): Overview

  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management

Pipeline Therapeutics

  • Comparative Analysis

Therapeutic Assessment

  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

Late Stage Products (Phase III)

  • Comparative Analysis

Emixustat hydrochloride: Kubota Vision

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Mid Stage Products (Phase II)

  • Comparative Analysis

ALK-001: Alkeus Pharmaceuticals

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Early Stage Products (Phase I/II)

  • Comparative Analysis

BPN-14967: Belite Bio

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Preclinical and Discovery Stage Products

  • Comparative Analysis

REV-0100: ReVision Therapeutics

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Inactive Products

  • Comparative Analysis

Stargardt Disease (STGD) Key Companies

Stargardt Disease (STGD) Key Products

Stargardt Disease (STGD)- Unmet Needs

Stargardt Disease (STGD)- Market Drivers and Barriers

Stargardt Disease (STGD)- Future Perspectives and Conclusion

Stargardt Disease (STGD) Analyst Views

Stargardt Disease (STGD) Key Companies

Appendix

List of Table

Table 1: Total Products for Stargardt Disease (STGD)

Table 2: Late Stage Products

Table 3: Mid Stage Products

Table 4: Early Stage Products

Table 5: Pre-clinical & Discovery Stage Products

Table 6: Assessment by Product Type

Table 7: Assessment by Stage and Product Type

Table 8: Assessment by Route of Administration

Table 9: Assessment by Stage and Route of Administration

Table 10: Assessment by Molecule Type

Table 11: Assessment by Stage and Molecule Type

Table 12: Inactive Products

List of Figures

Figure 1: Total Products for Stargardt Disease (STGD)

Figure 2: Late Stage Products                             

Figure 3: Mid Stage Products

Figure 4: Early Stage Products

Figure 5: Preclinical and Discovery Stage Products

Figure 6: Assessment by Product Type

Figure 7: Assessment by Stage and Product Type

Figure 8: Assessment by Route of Administration

Figure 9: Assessment by Stage and Route of Administration

Figure 10: Assessment by Molecule Type

Figure 11: Assessment by Stage and Molecule Type

Figure 12: Inactive Products   

• Kubota Vision

• Alkeus Pharmaceuticals

• IVERIC bio

• Generation Bio

• Nanoscope Therapeutics

• Stargazer Pharmaceuticals, Inc.

• Astellas Pharma

• Spark Therapeutics

• Katairo

• Vitrisa Therapeutics

• Biophytis

• Belite Bio

• Biogen

• ReVision Therapeutics

• Applied Genetic Technologies Corporation

• Beam Therapeutics

• Curative Biotechnology

• ProQR Therapeutics

• 4P-Pharma

• Coave Therapeutics

• Abeona Therapeutics

• Connectyx

Forward to Friend

Need A Quote